BIONET Therapeutics Corp. (TPEX:7808)

Market Cap	3.93B
Revenue (ttm)	105.67M
Net Income (ttm)	-100.46M
Shares Out	70.00M
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,940
Average Volume	28,032
Open	55.80
Previous Close	56.80
Day's Range	55.30 - 56.20
52-Week Range	37.70 - 66.30
Beta	n/a
RSI	42.29
Earnings Date	Mar 20, 2026

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2022
• Employees: 73
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7808

Financial Performance

In 2024, BIONET Therapeutics's revenue was 81.32 million, an increase of 1414.60% compared to the previous year's 5.37 million. Losses were -86.26 million, 131.0% more than in 2023.